Candel Therapeutics Overview
Valuation check: CADL's ROE is -9.89%, below the Healthcare sector average of 22.76%.
Get informed when a big investor buys or sells
+ Follow-9.89%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Candel Therapeutics (CADL) currently reports a ROE of -9.89%. That is below the Healthcare sector average of 22.76%. Use the charts on this page to explore Candel Therapeutics's ROE history and peer comparisons.
Candel Therapeutics's ROE of -9.89% is lower than the Healthcare sector average of 22.76%. That is roughly 143.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Candel Therapeutics's current -9.89% should be judged against Healthcare norms (sector average: 22.76%) and against CADL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -9.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Candel Therapeutics, and consider following CADL for alerts when major investors trade the stock.
Candel Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -9.89% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CADL with unrelated industries.
